NYSE:AZN
Astrazeneca P L C (AZN)
Financials 
Technical Analysis 
Jun 8, 2026, 12:00 amThis summary was created by AI, based on 8 opinions in the last 12 months.
AstraZeneca PLC (AZN-N) has shown impressive performance, with a 30% increase in share price over the past year and significant growth observed in its oncology business. Experts highlight a very advanced pipeline that is anticipated to drive substantial revenue, keeping the company on track to reach its ambitious long-term goals. The stock has displayed a consistent upward trend since 2022, indicating strong fundamentals. With a well-regarded cancer drug franchise and a portfolio considered superior to competitors, AstraZeneca is positioned for healthy growth as it aims for $80 billion in revenue by 2030. Moreover, the company trades at approximately 15 times earnings, boasting a 2% dividend yield, and has room for recovery in its share performance.
A diversified pharmaceutical, sort of shifting their business away from traditional fields. They are in decline right now on revenues. You want to be holding this along with Merck and Bristol-Myers. They have a very key study coming out, taking an immuno oncology drug and combining it with another immuno oncology drug. That is going to be a very key catalyst. Dividend yield of 4.5%. (Analysts’ price target is $34.)
Paul MacDonaldPfizer failed to acquire this company and the stock has dropped a lot. This trades at 14X earnings and has a great dividend yield and a great cash flow yield. Not expensive. Have some great things in their pipeline in the next little while, which will help the company out. Healthcare is a nice defensive area to be in if you are really worried about the stock market. (See Top Picks.)
Srikanth Iyer
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
It is rare he has puts on in his fund, but he does on this one. They have declining revenues, but a huge amount of data coming out about the next 12 to 18 months. We have seen the tip of the iceberg. He still likes it. It is not terribly expensive and has a high dividend. Own it with others for diversification. M&A would not surprise him in big pharma soon.